


**Product Name** : Fruquintinib  
**Cat. No.** : PC-45746  
**CAS No.** : 1194506-26-7  
**Molecular Formula** : C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub>  
**Molecular Weight** : 393.3927  
**Target** : VEGFR  
**Solubility** : DMSO: 7.75 mg/mL



### Biological Activity

Fruquintinib (HMPL-013) is a potent and highly selective small molecule inhibitor of **VEGFR1/2/3** with IC<sub>50</sub> of 33/3/5/0.5 nM, respectively.

Fruquintinib (HMPL-013) weakly inhibits RET, FGFR-1 and c-kit kinases.

Fruquintinib (HMPL-013) demonstrates potent inhibition on VEGF-A dependent KDR phosphorylation in HEK293-KDR cells and VEGF-A induced proliferation in primary HUVECs with IC<sub>50</sub> of 0.6 nM and 1.7 nM, respectively.

Fruquintinib (HMPL-013) suppresses tumor growth inhibition in a panel of tumor xenograft and patient derive xenograft models in mouse.

Fruquintinib (HMPL-013) is orally active.

### References

Sun Q, et al. *Cancer Biol Ther.* 2014;15(12):1635-45.

Gu Y, et al. *Cancer Chemother Pharmacol.* 2014 Jul;74(1):95-115.

Cao J, et al. *Cancer Chemother Pharmacol.* 2016 Aug;78(2):259-69.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com